# OnCo record peginterferon-alfa-2b (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/peginterferon-alfa-2b/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "peginterferon-alfa-2b" ;
  schema:name "Peginterferon alfa-2b"@en ;
  schema:description "Peginterferon alfa-2b, a long-acting interferon, was approved in 2011 as Sylatron for melanoma that had spread to lymph nodes and been removed, to delay recurrence; checkpoint inhibitors have since replaced it in that role."@en ;
  schema:url <https://onco.cc/drugs/peginterferon-alfa-2b/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Peginterferon_alfa-2b> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=peginterferon%20alfa-2b>, <https://en.wikipedia.org/wiki/Peginterferon_alfa-2b> ;
  onco:status "established" ;
  onco:tag "gap-fill", "chembl-universe" ;
  onco:modality "Pegylated type I interferon, weekly subcutaneous injection" ;
  schema:alternateName "Sylatron / PegIntron" ;
  onco:approval "US 2011: Adjuvant treatment of melanoma with nodal involvement after complete resection (Sylatron)" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/polycythaemia-vera/>, <https://onco.cc/cancers/essential-thrombocythaemia/> ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:targets <https://onco.cc/targets/ifnar1/> ;
  onco:drugs <https://onco.cc/drugs/interferon-alfa/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:trials <https://onco.cc/trials/nct01387763/>, <https://onco.cc/trials/nct00539591/> .